|Positive WB detected in
|Daudi cells, Raji cells, Ramos cells, RAW 264.7 cells
|Positive IF detected in
|Positive FC detected in
|Western Blot (WB)
|WB : 1:1000-1:4000
|IF : 1:50-1:500
|Flow Cytometry (FC)
|FC : 0.20 ug per 10^6 cells in a 100 µl suspension
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
13395-1-AP targets CD86 in WB, IF, FC, Cell treatment, ELISA applications and shows reactivity with human, mouse samples.
|human, mouse, rat
|Host / Isotype
|Rabbit / IgG
|CD86 fusion protein Ag4063
|Calculated molecular weight
|329 aa, 38 kDa
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Antigen affinity purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
CD86 (also known as B7.2) is a costimulatory molecule belonging to the immunoglobulin superfamily. Primarily expressed on antigen-presenting cells (APCs), including B cells, dendritic cells, and macrophages, CD86 is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of CD86 with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of CD86 with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. This antibody detects a band of approximately 65-70 kDa, consistent with glycosylated form of CD86 (PMID: 8592066, 21849678).
Engineered Bacterial Outer Membrane Vesicles as Controllable Two-way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor Immunotherapy
Acta Pharm Sin B
Converting bacteria into autologous tumor vaccine via surface biomineralization of calcium carbonate for enhanced immunotherapy
Adv Healthc Mater
A ROS-Responsive Liposomal Composite Hydrogel Integrating Improved Mitochondrial Function and Pro-Angiogenesis for Efficient Treatment of Myocardial Infarction.
Donor BMSC-derived small extracellular vesicles relieve acute rejection post-renal allograft through transmitting Loc108349490 to dendritic cells.
Bacterial navigation for tumor targeting and photothermally-triggered bacterial ghost transformation for spatiotemporal drug release.
ACS Appl Mater Interfaces
Surface Coating of Pulmonary siRNA Delivery Vectors Enabling Mucus Penetration, Cell Targeting, and Intracellular Radical Scavenging for Enhanced Acute Lung Injury Therapy.
The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.
Martin (Verified Customer) (09-28-2022)
Antibody is working very well